MAPT and Alzheimer disease: Based on a tau positivity cutoff of 2 SD greater than the mean of the Aβ+ HC group, 2 (5%) LBD participants, 5 (7%) HC participants and 17 (60%) Alzheimer’s disease participants were tau positive in entorhinal cortex; 3 (7%) LBD, 4 (6%) HC and 20 (71%) Alzheimer’s disease in inferior temporal cortex; 5 (12%) LBD, 3 (4%) HC and 16 (57%) Alzheimer’s disease in precuneus; and 3 (7%) LBD, 2 (3%) HC and 13 (46%) Alzheimer’s disease in lingual gyrus.